Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Kyprolis

- PMLiVE

Janssen and Legend Biotech’s Carvykti receives FDA approval for patients with relapsed or refractory multiple myeloma

In the study, 98% of patients with relapsed or refractory multiple myeloma responded to a one-off treatment of the drug

- PMLiVE

FDA issues approval for Janssen’s HIV drug Cabenuva

The injectable treatment for adults with HIV can be administered every two months

- PMLiVE

Janssen submits marketing authorisation to EMA for teclistamab

The drug has been developed to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer

- PMLiVE

Janssen’s Tremfya receives positive results for active psoriatic arthritis

The drug demonstrated positive joint efficacy and ranked highest for skin clearance when compared to existing therapies

- PMLiVE

NICE recommends long-acting HIV therapy developed by ViiV Healthcare and Janssen

People with HIV-1 in England and Wales can swap their daily tablets for a two-monthly injection regimen from 2022, joining HIV patients in Europe and the US

- PMLiVE

Janssen’s RSV vaccine provides high protection against respiratory infections

The phase 2b data showed the RSV vaccine provided 80% protection against lower respiratory infections in adults aged 65 and older

- PMLiVE

FDA nod for Janssen schizophrenia treatment Invega Hafyera

The phase 3 study results showed that 92% of patients were relapse-free after 12 months

- PMLiVE

EC approves BMS cell therapy for multiple myeloma

The approval of Abecma is based on “rapid, deep and durable” trial responses

- PMLiVE

FDA grants orphan drug status to Allogene’s BCMA-targeted treatment for multiple myeloma

The decision follows the RMAT designation granted by the FDA in April

- PMLiVE

Sanofi signs $1bn licence agreement for Eureka’s novel multiple myeloma drug

Multiple myeloma is the second most common blood cancer

- PMLiVE

J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma

Darzalex treatment regimen reduced risk of death by 32% after nearly five years follow-up

- PMLiVE

FDA priority review granted for J&J, Legend Biotech’s myeloma CAR T therapy

CAR T therapy demonstrated an overall response rate of 97% in relapsed/refractory multiple myeloma patients after 12.4 months

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links